Overview

• Eyecare tech firm's Q4 revenue grew 7% yr/yr, meeting analyst expectations

• Company reduced Q4 operating expenses by 25% yr/yr

• 2026 revenue expected to grow 6% to 14%

Outlook

• Sight Sciences expects 2026 revenue between $82 mln and $88 mln, up 6% to 14%

• Company forecasts Interventional Glaucoma revenue of $77 mln to $81 mln in 2026

• Sight Sciences anticipates Interventional Dry Eye revenue of $5 mln to $7 mln in 2026

Result Drivers

• INTERVENTIONAL GLAUCOMA - Revenue growth driven by higher average selling prices and increased ordering accounts

• INTERVENTIONAL DRY EYE - Revenue increase due to higher average selling prices

• EXPENSE REDUCTION - Operating expenses decreased 25% due to lower personnel-related expenses and stock-based compensation

Company press release: ID:nGNX3FHLNF

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Sight Sciences Inc is $9.05, about 72.1% above its March 3 closing price of $5.26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)